The International Society for Vaccines is an organization that engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines - 2017 ISV Annual Congress

Paper of the Month Feb 2016

A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease.

J Immunol. 2016 Feb 15;196(4):1721-31. doi: 10.4049/jimmunol.1502103. Epub 2016 Jan 20.

Authors

Li C, Zhou X, Zhong Y, Li C, Dong A, He Z, Zhang S, Wang B.

Abstract

Respiratory syncytial virus (RSV) infection can cause severe disease in the lower respiratory tract of infants and older people. Vaccination with a formalin-inactivated RSV vaccine (FI-RSV) and subsequent RSV infection has led to mild to severe pneumonia with two deaths among vaccinees. The vaccine-enhanced disease (VED) was recently demonstrated to be due to an elevated level of Th2 cell responses following loss of regulatory T (Treg) cells from the lungs. To induce high levels of neutralizing Abs and minimize pathogenic T cell responses, we developed a novel strategy of immunizing animals with a recombinant RSV G protein together with cyclosporine A. This novel vaccine induced not only a higher level of neutralizing Abs against RSV infection, but, most importantly, also significantly higher levels of Treg cells that suppressed VED in the lung after RSV infection. The induced responses provided protection against RSV challenge with no sign of pneumonia or bronchitis. Treg cell production of IL-10 was one of the key factors to suppress VED. These finding indicate that G protein plus cyclosporine A could be a promising vaccine against RSV infection in children and older people.

Paper of the Month Jan 2016

Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.

J Infect Dis. 2016 Jan 21. pii: jiv748. [Epub ahead of print]

Authors

Bruce MG et al Arctic Investigations program, Division of Preparedness and Emerging Infections, National Center from Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention

Background

The duration of protection in children and adults resulting from hepatitis B vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska native adults and children from 15 Alaska communities aged >= 6 months using 3 does of plasma-derived hepatitis B vaccine.